Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer

Cancer Cell. 2019 Apr 15;35(4):535-537. doi: 10.1016/j.ccell.2019.03.008.

Abstract

In this issue of Cancer Cell, Liao et al. demonstrate that oncogenic KRAS drives an immune suppressive program in colorectal cancer by repressing IRF2 expression, which leads to downregulation of interferon responsive genes, enhanced expression of CXCL3 and recruitment of suppressive myeloid cells, and subsequent resistance to immune checkpoint blockade.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Colonic Neoplasms*
  • Colorectal Neoplasms / genetics*
  • Genes, ras
  • Humans
  • Interferon Regulatory Factor-2
  • Oncogenes
  • Proto-Oncogene Proteins p21(ras)

Substances

  • IRF2 protein, human
  • Interferon Regulatory Factor-2
  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)